← Back to Search

GLS-5310 Vaccine for COVID-19

Phase 1
Waitlist Available
Research Sponsored by GeneOne Life Science, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 48 weeks post vaccination
Awards & highlights

Study Summary

This trial is testing a new vaccine to see if it is safe and effective in people who have already been vaccinated against Covid-19.

Eligible Conditions
  • COVID-19
  • Coronavirus
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 48 weeks post vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 48 weeks post vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine antibody responses after a single dose of vaccine
Incidence of adverse events
Secondary outcome measures
Evaluation of neutralizing antibody response induced by GLS-5310 relative to treatment arm
Evaluation of positive response rate of T cell responses induced by GLS-5310 DNA vaccine

Trial Design

4Treatment groups
Experimental Treatment
Group I: GLS-5310 ID + GeneDerm 80 kPa, 30 secondsExperimental Treatment1 Intervention
GLS-5310 ID + GeneDerm administered at Visit 1
Group II: GLS-5310 ID + GeneDerm 65 kPa, 30 seconds + GLS-5310 INExperimental Treatment1 Intervention
GLS-5310 ID + GeneDerm + GLS-5310 IN administered at Visit 1
Group III: GLS-5310 ID + GeneDerm 65 kPa, 30 secondsExperimental Treatment1 Intervention
GLS-5310 ID + GeneDerm administered at Visit 1
Group IV: GLS-5310 ID + GeneDerm 65 kPa, 15 secondsExperimental Treatment1 Intervention
GLS-5310 ID + GeneDerm administered at Visit 1

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

GeneOne Life Science, Inc.Lead Sponsor
15 Previous Clinical Trials
1,371 Total Patients Enrolled
4 Trials studying COVID-19
529 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the study allow minors to participate?

"This medical experiment is welcoming volunteers who are of legal age and not exceeding 65 years old."

Answered by AI

Who meets the criteria for participating in this clinical experiment?

"This clinical trial is seeking 69 participants aged 18 to 65 with a confirmed diagnosis of Covid-19. To be eligible, applicants must provide written consent and agree to comply with the study's protocols, including abstaining from other vaccinations for 4 weeks after receiving the drug in question. Additionally, female candidates of childbearing potential are expected to use approved forms of contraception during this period. Finally, all candidates must have previously completed at least one vaccination series using either BNT162b2, mRNA-1273 or Ad26.CoV.S vaccine within 6 months prior their enrolment into this program."

Answered by AI

What implications does GLS-5310 (Group 2) have for patient health?

"Due to the preliminary nature of this clinical trial, GLS-5310 (Group 2) was estimated by our team at Power as having a safety rating of 1. This is because Phase 1 trials have limited research backing up their efficacy and security."

Answered by AI

Are any opportunities still available to join this experiment?

"This research endeavour, which was initially listed on May 23rd 2022 and last edited about a month ago, is not currently accepting participants. Nevertheless, 1862 other clinical trials are open to enrollment at this time."

Answered by AI

Who else is applying?

What state do they live in?
Puerto Rico
Maryland
Nebraska
How old are they?
18 - 65
What site did they apply to?
Meridian Clinical Research
Clinical Research Puerto Rico
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
2022. "GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05182567.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top